ESMO: Keytruda, Padcev reduce risk of death by 50% in another massive showing in bladder cancer
Pfizer and Astellas, in partnership with Merck & Co., reported that the antibody-drug Padcev and the immunotherapy Keytruda reduced the risk of death by 50 percent in patients with muscle-invasive bladder cancer.
Results from the Phase 3 Keynote-905 trial showed major survival benefits for patients who were not eligible for cisplatin-based chemotherapy. Johanna Bendell, M.D., Pfizer’s oncology chief development officer, said the companies believe both presurgical and postsurgical treatment are key to the regimen’s success, adding that “with data strong like this, it makes it much easier to have those discussions.”
These findings highlight Pfizer’s leadership in advancing oncology innovation, reinforcing the Pacific Northwest’s role in global cancer research and next-generation treatment development.